Increasing vaccine potency through exosome antigen targeting. - Wikidata - awgldk - TriplyDB

Increasing vaccine potency through exosome antigen targeting.

Increasing vaccine potency through exosome antigen targeting.

http://www.wikidata.org/entity/Q35955224

about

The Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt?Towards Therapeutic Delivery of Extracellular Vesicles: Strategies for In Vivo Tracking and Biodistribution Analysis The role of Merkel cell polyomavirus and other human polyomaviruses in emerging hallmarks of cancer Acute stressor exposure modifies plasma exosome-associated heat shock protein 72 (Hsp72) and microRNA (miR-142-5p and miR-203)From notochord formation to hereditary chordoma: the many roles of Brachyury.Nucleolin-targeted Extracellular Vesicles as a Versatile Platform for Biologics Delivery to Breast Cancer.Regulation of HIV-Gag expression and targeting to the endolysosomal/secretory pathway by the luminal domain of lysosomal-associated membrane protein (LAMP-1) enhance Gag-specific immune response.Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions What are exosomes and how can they be used in multiple sclerosis therapy?FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver.Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated forms HPV-E7 delivered by engineered exosomes elicits a protective CD8⁺ T cell-mediated immune response Therapeutic applications of extracellular vesicles: clinical promise and open questions.Potential functional applications of extracellular vesicles: a report by the NIH Common Fund Extracellular RNA Communication Consortium Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma.Preclinical HER-2 Vaccines: From Rodent to Human HER-2 The biological significance and clinical applications of exosomes in ovarian cancer.Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation Pancreatic cancer diagnosis by free and exosomal miRNA.Exosomes as nanocarriers for siRNA delivery: paradigms and challenges.The CD8⁺ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIXTM Adjuvant.IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.Microvesicles as mediators of tissue regeneration.Exosome mimetics: a novel class of drug delivery systems.Exosomes and communication between tumours and the immune system: are all exosomes equal?Exosome analysis: a promising biomarker system with special attention to saliva.Targeting soluble proteins to exosomes using a ubiquitin tag.Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice.Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics.Biochemical and proteomic characterization of retrovirus Gag based microparticles carrying melanoma antigens.Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation.A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents.Incorporation of Heterologous Proteins in Engineered Exosomes.Affinity biosensors using recombinant native membrane proteins displayed on exosomes: application to botulinum neurotoxin B receptor.Exosome Theranostics: Biology and Translational Medicine.Biological Functions and Current Advances in Isolation and Detection Strategies for Exosome Nanovesicles.Aptamer-conjugated extracellular nanovesicles for targeted drug delivery.CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8+ T Cell Responses.Therapeutic biomaterials based on extracellular vesicles: classification of bio-engineering and mimetic preparation routes.

P2860

Q26773307-2B9FEAE7-F175-407B-96C2-2D450DC10FEE Q28075450-02C134FD-88DD-4BA9-8544-9219D36A031E Q28083883-1C7B62B1-9E80-4019-A7A3-DEA3FA939D85 Q28543347-28301944-9BB3-4B83-8F2E-F7C9E348F9B0 Q33274793-8FE563F8-3C2D-448D-AB7E-FBFFA67CAF4A Q33588257-E71C7F03-8CD6-4554-8E47-288E291E9D11 Q33763297-BEF48631-F5FF-4A14-B995-A56E4B860FD5 Q33791173-4A521E89-D622-4DEB-AD33-EB3E03C743DF Q33875923-79A6B30C-A6C3-49F6-9FDB-48B7F0E066FA Q34037648-5396C081-4A46-4C5A-A2C2-DD3A54521E54 Q34111151-EB189034-5A53-45AB-B1D8-677F3771BC8F Q35232797-E34903B6-7CC1-4364-9437-E7E8222863A8 Q35654719-8D906112-C99D-4AB8-B905-F73CF6FCCF30 Q36006436-8721E48B-BC15-4507-8514-D616478E3CC3 Q36422761-0340564A-4880-472B-893D-98047C38D31C Q36880469-B09A6497-5606-4D7A-ACBB-F7E75305523C Q36914661-99291067-F643-4826-AFC3-97A1C426A3A5 Q37029851-6BE4E24E-7D57-402C-BE11-486771D4DBE7 Q37141136-00E2A910-E0B6-4F63-B13D-F5139E0BECBA Q37382231-975472A9-45AE-4D72-9FC3-DA73469D8761 Q37412689-111D57F6-61C7-48DE-BEAE-B63C7868C8E0 Q37539231-98D3BEFE-1B99-42AA-93D1-8C63F45D3F2D Q37576782-E7CF741C-071B-426C-8C4E-A012958BB747 Q37686479-1A0EF391-7985-4A5A-A759-2D7AD78E3A73 Q38012446-DFB1F07B-C891-4E7E-B698-DF4F48AB2184 Q38077239-241FAF7D-E506-4D2D-9EF5-7BB8B119B50F Q38241070-0F77F316-1113-4B60-9633-A6B6A0D52D3B Q38819123-BAC8179E-5909-4128-AEC6-71F7750681C5 Q38971206-3E6A4A6C-BF31-4A5A-9109-3B1693527D2C Q39076891-D39A2AB4-7F1E-4245-BE55-56C943B9A5CA Q39610714-FF7CB64C-69D1-4556-9181-708CDA09E93C Q40140715-137DCAFE-ED84-41CF-8008-73BA6BB0CD07 Q40437431-CF2E55AF-C39F-4546-BEE1-D95F38622544 Q42102335-0FA293A4-2A10-4D23-9A3C-42D8C8771D06 Q42108314-2EA2D71E-9540-44CA-992D-ADC893E00650 Q47095746-D9922EF0-0F89-48C3-96F1-A9A674BD7D75 Q47250358-D55AEDA5-4BA8-43EC-A96E-F859ED0DB66A Q47271340-B7FD0C90-5D71-42F6-A768-0DAE7A8B5C62 Q48142387-7A6FD539-1346-4CB8-BCAA-D21BE936100C Q48162156-3C1D331B-EBA8-493B-AF0D-A777CD1F8454

P2860

Increasing vaccine potency through exosome antigen targeting.

http://www.wikidata.org/entity/Q35955224

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Increasing vaccine potency through exosome antigen targeting.

@ast

Increasing vaccine potency through exosome antigen targeting.

@en

type

label

Increasing vaccine potency through exosome antigen targeting.

@ast

Increasing vaccine potency through exosome antigen targeting.

@en

prefLabel

Increasing vaccine potency through exosome antigen targeting.

@ast

Increasing vaccine potency through exosome antigen targeting.

@en

P1433

Q35955224-89F82492-0563-4AFB-BE9C-58D288206355

P1476

Q35955224-F12E5484-542A-42A6-9ADC-0611F86C4F20

P2093

Q35955224-17BD0CC0-FC1A-420A-9143-79DE48B95E96

Q35955224-4844ED46-03B4-498F-A193-6E933AD2AE60

Q35955224-510F7781-B545-43C5-A411-45A0D6C16582

Q35955224-547610E2-9D23-4DA3-99CA-E3E5737E3D2F

Q35955224-56A47F72-FFAF-4DBE-BB69-05F8DEB1ABE6

Q35955224-587ECF44-B081-4DEE-8F9F-69776EDC3DC5

Q35955224-69E96EB0-848C-48A4-AD1C-B252D6923001

Q35955224-9A05B458-FA69-4B53-9729-B20EDE7647DB

Q35955224-9EE94583-1234-4ACF-86A7-ED73C40E6E86

Q35955224-DE420C06-3BA3-4696-A9E8-E70697000B19

P2860

Q35955224-23148529-877E-436D-AEDD-2A6AE8C2A73C

Q35955224-2C345CEA-1FAD-4094-BC10-E2CF67BD4D13

Q35955224-2D6AE788-E9C9-40E2-807D-DFD9EA812912

Q35955224-3936B208-7E80-431A-B51F-3617CDB1B9AF

Q35955224-437A2E7B-06B3-4DC5-B0F1-ADD6C5FF8264

Q35955224-4B0EB4CC-10C8-4C4B-B632-A589EB838535

Q35955224-5805BBEB-2EAB-4DC7-A74D-0B73D76A7672

Q35955224-6940425A-5F14-44C7-B097-07D295B0781C

Q35955224-7A0C9FA1-3C94-4227-873F-9EFB0BC09BB9

Q35955224-90A46048-E2EF-4D21-B8A9-FD127B224AFE

P304

Q35955224-253BCA74-ED49-4F77-A3D3-1E59BFC12369

P31

Q35955224-0B949A50-3EB7-4AA9-9CDF-1EB5CB69800C

P356

Q35955224-687FF2BC-3A3A-4F75-929A-66794F47E8BE

P407

Q35955224-315E0678-4AB6-4856-B632-EFFEAACB3119

P433

Q35955224-BE3413D2-0850-42FB-AE0F-259D6C4B5DCE

P478

Q35955224-55B3C89A-2950-4A5C-BC39-47D76E40A393

P50

Q35955224-6784513B-9997-4D79-8AF5-AE762D924444

P577

Q35955224-9F0F904C-4E18-47C5-BE18-F458937A00BC

P5875

Q35955224-067C0232-6756-41B8-B27F-B13A0A9FD7C3

P698

Q35955224-21C121D0-8A67-402C-8F23-A4D01BC80309

P932

Q35955224-526815F2-9822-4D7B-9CDA-831B4D1B571F

P356

J.VACCINE.2011.09.133

P1433

P1476

Increasing vaccine potency through exosome antigen targeting.

@en

P2093

Alain Delcayre

http://www.w3.org/2001/XMLSchema#string

Amy Hobeika

http://www.w3.org/2001/XMLSchema#string

Gangjun Lei

http://www.w3.org/2001/XMLSchema#string

Hongtao Guo

http://www.w3.org/2001/XMLSchema#string

Jean-Bernard Le Pecq

http://www.w3.org/2001/XMLSchema#string

Junping Wei

http://www.w3.org/2001/XMLSchema#string

Michael A Morse

http://www.w3.org/2001/XMLSchema#string

Oliver K Glass

http://www.w3.org/2001/XMLSchema#string

Takuya Osada

http://www.w3.org/2001/XMLSchema#string

Timothy M Clay

http://www.w3.org/2001/XMLSchema#string

P2860

A simplified system for generating recombinant adenoviruses

Crystal structure of the bovine lactadherin C2 domain, a membrane binding motif, shows similarity to the C2 domains of factor V and factor VIII

Secretion of a peripheral membrane protein, MFG-E8, as a complex with membrane vesicles

Exosomes: composition, biogenesis and function

Membrane vesicles as conveyors of immune responses

Exosome Display technology: applications to the development of new diagnostics and therapeutics.

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.

An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.

Exosome: from internal vesicle of the multivesicular body to intercellular signaling device.

Exosomes and cancer: a newly described pathway of immune suppression.

P304

9361-9367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2011.09.133

http://www.w3.org/2001/XMLSchema#string

P407

P433

50

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Herbert Kim Lyerly

P577

2011-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51719282

http://www.w3.org/2001/XMLSchema#string

P698

22001882

http://www.w3.org/2001/XMLSchema#string

P932

3350974

http://www.w3.org/2001/XMLSchema#string